Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital.

Led by a highly experienced management team and world-renowned experts in tumor biology, an extensive research program has focused on engineering synthetic peptides with unique, antitumoral properties.

CyPep-1, the company’s lead candidate, is being developed as a first-in-class tumor membrane targeting agent for the treatment of solid tumors.